Tag: Kevin Guan
Three firms act on BioNTech’s USD950m China partner buyout
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
Life insurers’ digital shift demands stronger legal oversight to protect customer data and cyber resilience
Follow us on LinkedIn